Renovaro Biosciences Balance Sheet

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Year	2023	2022	2021	2020	2019	2018	2017
Cash & Equivalents	1.87	9.17	20.66	8.7	12.28	15.6	3.94
Cash & Cash Equivalents	1.87	9.17	20.66	8.7	12.28	15.6	3.94
Cash Growth	-79.56%	-55.61%	137.62%	-29.20%	-21.27%	295.51%	-
Receivables	0	0	0	0	0.02	0.12	0.22
Other Current Assets	0.69	0.39	0.23	0.24	0.19	0.04	0.03
Total Current Assets	2.57	9.57	20.9	8.94	12.49	15.76	4.2
Property, Plant & Equipment	1.42	1.74	2.16	2.48	0.69	0.03	0
Long-Term Investments	0	0	0	0	0	0	0.2
Goodwill and Intangibles	54.29	73.26	166.53	166.54	166.56	166.58	0.12
Other Long-Term Assets	0.02	0.07	0.02	0.14	0.14	0.14	0
Total Long-Term Assets	55.74	75.07	168.71	169.16	167.38	166.74	0.32
Total Assets	58.3	84.63	189.61	178.1	179.88	182.5	4.52
Accounts Payable	5.3	1.4	0.32	0.59	0.77	0.81	0.67
Current Debt	4.82	1.45	0.29	0.27	0	0	2.09
Other Current Liabilities	0.91	3.6	1.27	0.47	0.34	0.07	0.23
Total Current Liabilities	11.02	6.45	1.89	1.33	1.11	0.87	2.99
Long-Term Debt	0.78	5.56	7.02	7.31	0	0	0
Other Long-Term Liabilities	0	0	6.04	3.18	5.67	22.89	0
Total Long-Term Liabilities	0.78	5.56	13.06	10.5	5.67	22.89	0
Total Liabilities	11.8	12.01	14.94	11.83	6.78	23.76	2.99
Total Debt	5.59	7.02	7.31	7.58	0	0	2.09
Debt Growth	-20.27%	-4.03%	-3.60%	-	-	-	-
Retained Earnings	-244.03	-204.35	-90.91	-64.19	-52.77	-34.76	-28.44
Comprehensive Income	-0.03	-0.03	-0.01	-0.04	0.1	0.21	0.35
Shareholders' Equity	46.5	72.62	174.66	166.27	173.1	158.74	1.53
Net Cash / Debt	-3.72	2.16	13.35	1.11	12.28	15.6	1.85
Net Cash / Debt Growth	-	-83.86%	1100.31%	-90.94%	-21.27%	741.20%	-
Net Cash Per Share	-0.07	0.04	0.28	0.02	0.33	0.71	0.15
Working Capital	-8.46	3.11	19.01	7.61	11.38	14.89	1.21
Book Value Per Share	0.83	1.38	3.70	3.59	4.61	7.24	0.13

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).